Angiogénese
Os inibidores da angiogênese são compostos que interferem na formação de novos vasos sanguíneos, um processo crítico no crescimento e metástase do câncer. Ao inibir a angiogênese, esses compostos podem restringir o suprimento de sangue para os tumores, retardando ou interrompendo seu crescimento. Os inibidores da angiogênese são essenciais na pesquisa do câncer e no desenvolvimento terapêutico, fornecendo insights sobre os mecanismos de progressão tumoral e oferecendo potenciais tratamentos para o câncer e outras doenças relacionadas à angiogênese. Na CymitQuimica, oferecemos uma ampla gama de inibidores da angiogênese de alta qualidade para apoiar sua pesquisa em oncologia e biologia vascular.
Subcategorias de "Angiogénese"
- BTK(165 produtos)
- Bcr-Abl(117 produtos)
- EGFR(562 produtos)
- FAK(72 produtos)
- FLT(89 produtos)
- Receptor do Factor de Crescimento Fibroblasto (FGFR)(177 produtos)
- JAK(245 produtos)
- PDGFR(127 produtos)
- RAAS(86 produtos)
- Src(82 produtos)
- Syk(37 produtos)
- Trombina(52 produtos)
- VDA(2 produtos)
- VEGFR(239 produtos)
Exibir 6 mais subcategorias
Foram encontrados 2243 produtos de "Angiogénese"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
Emavusertib hydrochloride
CAS:Emavusertib (CA-4948) hydrochloride, a selective and potent IRAK4/FLT3 inhibitor, is designed for oral administration. It achieves an IC 50 of 57 nM against IRAK4 in a FRET kinase assay and demonstrates anti-tumor activity [1] [2] [3].Fórmula:C24H26ClN7O5Cor e Forma:SolidPeso molecular:527.96BTK-IN-37
BTK-IN-37 (compound 8d), a BTK inhibitor, demonstrates potent apoptotic effects on cancer cells by targeting BTK with K_i and IC_50 values of 5.07 nM and 3.6 nM, respectively. Additionally, this compound selectively promotes the enrichment of genes associated with necroptosis and pyroptosis.Fórmula:C29H29N9O4SCor e Forma:SolidPeso molecular:599.66HSK205
HSK205 is a dual FLT3 and haspin inhibitor, exhibiting potent antitumor activity [1], with an IC50 of 0.187 nM for FLT3.Cor e Forma:Odour SolidEGFR/CDK2-IN-4
EGFR/CDK2-IN-4 (compound 4c) is a dual inhibitor targeting EGFR and CDK-2, demonstrating IC50 values of 89.6 nM for EGFR and 165.4 nM for CDK-2.Fórmula:C24H16N6OS2Pureza:98%Cor e Forma:SolidPeso molecular:468.55ML228
CAS:ML228 activates HIF pathway and VEGF, with EC50 of 1μM, effective in vitro.Fórmula:C27H21N5Pureza:99.54%Cor e Forma:SolidPeso molecular:415.49hCA/VEGFR-2-IN-1
hCA/VEGFR-2-IN-1 (compound 13a) is a potent dual inhibitor targeting both Carbonic Anhydrase (CA) IX/XII and Vascular Endothelial Growth Factor Receptor 2 (Fórmula:C21H17FN6O3SPureza:98%Cor e Forma:SolidPeso molecular:452.46DSPE-PEG5000-GE11
DSPE-PEG5000-GE11 is a PEG compound composed of DSPE and the EGFR-targeting peptide (GE11). GE11 is applicable for cancer cells with EGFR overexpression. DSPE-PEG5000-GE11 is utilized in drug delivery.Cor e Forma:Odour SolidGBD-9
CAS:GBD-9, a dual-mechanism degrader, effectively promotes the degradation of BTK and GSPT1 through recruitment of E3 ligase cereblon (CRBN).Fórmula:C44H47N9O6Pureza:98%Cor e Forma:SolidPeso molecular:797.9DSPE-PEG1000-GE11
DSPE-PEG1000-GE11 is a PEG compound made up of DSPE and an EGFR-targeting peptide (GE11). GE11 is applicable for cancer cells overexpressing EGFR. DSPE-PEG1000-GE11 serves a role in drug delivery.Cor e Forma:Odour SolidSI-2
CAS:SI-2, a SRC-3 inhibitor, triggers breast cancer cell death (IC50: 3-20 nM), sparing normal cells.Fórmula:C15H15N5Pureza:98.4%Cor e Forma:SolidPeso molecular:265.31Ref: TM-T28773
1mg378,00€5mg922,00€10mg1.225,00€25mg1.853,00€50mg2.490,00€100mg3.353,00€1mL*10mM (DMSO)845,00€7-Hydroxyneolamellarin A
CAS:7-Hydroxyneolamellarin A, from Dendrilla nigra, inhibits HIF-1α and VEGF in cancer research.Fórmula:C24H19NO5Cor e Forma:SolidPeso molecular:401.41ALK-IN-12
CAS:ALK-IN-12: potent ALK inhibitor (IC50: 0.18 nM), affects IGF1R and InsR (IC50: 20.3/90.6 nM), potential for cancer therapy.Fórmula:C24H30ClN6O2PCor e Forma:SolidPeso molecular:500.97Erlotinib-13C6
CAS:Erlotinib-13C6 (CP-358774-13C6), a 13C-labeled direct EGFR inhibitor, IC50: 2 nM.Fórmula:C22H23N3O4Cor e Forma:SolidPeso molecular:399.397EGFR/DHFR-IN-2
EGFR/DHFR-IN-2 (9b) is a dual inhibitor of h-DHFR/EGFR TK, exhibiting IC50 values of 0.192 μM for h-DHFR and 0.109 μM for EGFR. It causes cell cycle arrest at the G1/S phase and induces apoptosis. Additionally, EGFR/DHFR-IN-2 (9b) is a potential inhibitor of CYP2C9 and CYP3A4. This compound can be utilized in cancer research.Fórmula:C24H16N4O5Cor e Forma:SolidPeso molecular:440.11207DA5-HTL
DA5-HTL is a compound that combines dasatinib with the HaloTag system, effectively inhibiting the growth of tumor cells, with a GI50 of 1.923 nM.Fórmula:C39H58Cl2N8O8SPeso molecular:868.34754EGFR kinase inhibitor 2
EGFR kinase inhibitor 2 (compound A-7) is a potent EGFR inhibitor targeting the mutations EGFRL858R/T790M/C797S and EGFRDel19/T790M/C797S. This compound shows potential in addressing acquired resistance in the treatment of non-small cell lung cancer.Fórmula:C39H40N6O5Peso molecular:672.30602HER2/neu (654-662) GP2
CAS:Phage display selected Affibody ligands for HER2/neu from a protein library based on a 58-residue Staphylococcal protein A Z domain.Fórmula:C42H77N9O11Pureza:98%Cor e Forma:SolidPeso molecular:884.11DC-Srci-6649
CAS:DC-Srci-6649 is a potent and selective inhibitor of c-Src kinase, effectively blocking its phosphorylation and stabilizing it in an inactive conformation.Fórmula:C20H22Cl2N2O2SCor e Forma:SolidPeso molecular:425.37JAK/HDAC-IN-2
JAK/HDAC-IN-2, a potent 2-amino-4-phenylaminopyrimidine dual-target inhibitor, effectively suppresses JAK1/2 and HDAC3/6 at nanomolar concentrations.Fórmula:C28H38N6O5SPureza:98%Cor e Forma:SolidPeso molecular:570.7ZSH-2117
ZSH-2117 is a covalent and selective EGFR PROTAC degrader, with a DC50 of 45 nM in Ba/F3-EGFR[L858R/T790M/C797S] cells. It significantly inhibits cell proliferation and reduces AKT and ERK protein levels in downstream EGFR signaling pathways. ZSH-2117 effectively suppresses tumor growth in Ba/F3-EGFR[L858R/T790M/C797S] xenograft mouse models.Cor e Forma:Odour Solid
